Details

Autor(en) / Beteiligte

• Myles, Paul S
• Smith, Julian A
• Forbes, Andrew
• Silbert, Brendan
• Jayarajah, Mohandas
• Painter, Thomas
• Cooper, D. James
• Marasco, Silvana
• McNeil, John
• Bussières, Jean S
• Wallace, Sophie

Titel

Stopping vs. Continuing Aspirin before Coronary Artery Surgery

Ist Teil von

• The New England journal of medicine, 2016-02, Vol.374 (8), p.728-737

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• In a randomized trial involving 2100 patients undergoing coronary artery surgery, the risk of bleeding within 30 days after surgery was not higher with aspirin than with placebo, nor was the risk of death or thrombosis within 30 days after surgery lower with aspirin than with placebo. Most patients with coronary artery disease take aspirin for primary or secondary prevention of thrombotic events. 1 Aspirin inhibits platelet function and therefore poses an increased risk of bleeding among patients undergoing coronary artery bypass grafting (CABG), 1 although this risk appears to be small. 2 – 5 Until recently, it has been traditional practice in most cardiac surgical centers to have patients stop taking aspirin 5 to 7 days before surgery to reduce the risk of bleeding. However, the increased risk of surgical bleeding could be outweighed by the beneficial effect of aspirin on coronary-graft flow and on reduction in the risk of . . .